-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Obstructive sleep apnea and cardiovascular risk
(2476) Views (263) Full article downloads
Author: Punginathn Dorasamy
Published Date January 2007
Volume 2007:3(6) Pages 1105 - 1111
DOI: http://dx.doi.org/10.2147/TCRM.S
Punginathn Dorasamy
Pulmonary Hypertension Clinic, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
Abstract: Obstructive sleep apnea (OSA) is a form of sleep disordered breathing characterized by episodes of apnea (during sleep) lasting at least 10 seconds per episode. The apneic periods are associated with arterial hypoxemia and disruption of normal sleep as a result of awakenings. It is increasingly being recognized that OSA is a public health hazard and there is increasing evidence that it is associated with an increase in morbidity (and possibly mortality). Patients with OSA also utilize the healthcare resources at higher rates than control patients long before their diagnosis is confirmed. Early recognition of this condition may lead to earlier treatments (eg, nasal CPAP) with reduction of the risk of cardiovascular diseases such as hypertension, ischemic heart disease, arrhythmias, platelet activation and
pulmonary hypertension.
Keywords: obstructive sleep apnea (OSA), apnea-hypopnea index (AHI), polysomnography, overlap syndrome, C-Reactive protein (CRP), sleep disordered breathing (SDB), Cheynes Stokes respiration-central sleep apnea (CSR-CSA)
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




